Finance

Beta
Lists
NATCOPHARM:NSE
Natco Pharma Ltd
₹893.00
-2.80%
(-25.70) 1D
Jun 5, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for NATCOPHARM...
Open
₹924.00
High
₹924.00
Low
₹888.60
Mkt. cap
160.13B
Avg. vol.
825.12K
Volume
1.24M
Dividend
0.56%
Quarterly dividend
₹1.25
Ex-dividend date
Feb 18, 2026
P/E ratio
11.28
52-wk high
₹1,226.80
52-wk low
₹789.00
EPS
₹79.20
Shares outstanding
182.26M
No. of employees
4K
Open
₹924.00
High
₹924.00
Low
₹888.60
Mkt. cap
160.13B
Avg. vol.
825.12K
Volume
1.24M
Dividend
0.56%
Quarterly dividend
₹1.25
Ex-dividend date
Feb 18, 2026
P/E ratio
11.28
52-wk high
₹1,226.80
52-wk low
₹789.00
EPS
₹79.20
Shares outstanding
182.26M
No. of employees
4K
News stories
From sources across the web
Profile
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs at affordable prices. Wikipedia
About Natco Pharma Ltd
CEORajeev Nannapaneni
Employees4.2K
Founded1981
HeadquartersBanjara Hills, Telangana, India
SectorPharmaceutical industry
Last report
May 29, 2026
Fiscal period
Q4 2026
EPS / Est. (INR)
₹14.96 / ₹7.69
+94.54%beat
Revenue / Est. (INR)
7.39B / 6.57B
+12.49%beat
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
13.29B
13.63B
6.47B
7.39B
Cost of goods sold
2.33B
1.70B
1.33B
1.55B
Cost of revenue
2.33B
1.70B
1.33B
1.55B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.69B
2.00B
1.59B
1.58B
Operating expense
5.82B
6.66B
4.02B
5.07B
Total operating expenses
8.16B
8.36B
5.35B
6.62B
Operating income
5.13B
5.27B
1.12B
772.00M
Other non operating income
617.00M
1.00B
581.00M
778.00M
EBT including unusual items
5.72B
6.14B
1.72B
1.80B
EBT excluding unusual items
5.72B
6.14B
1.72B
1.80B
Income tax expense
916.00M
958.00M
207.00M
-892.00M
Effective tax rate
16.02%
15.61%
12.03%
-49.61%
Other operating expenses
3.56B
4.14B
1.96B
2.98B
Net income
4.81B
5.18B
1.52B
2.68B
Net profit margin
36.17%
38.03%
23.40%
36.25%
Earnings per share
26.84
28.94
8.46
14.96
Interest and investment income
-
-
-
-
Interest expense
-32.00M
-131.00M
-95.00M
-109.00M
Net interest expenses
-32.00M
-131.00M
-95.00M
-109.00M
Depreciation and amortization charges
576.00M
524.00M
462.00M
504.00M
EBITDA
5.72B
5.82B
1.57B
1.29B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more